Treating patients with aspirin after completion of standard adjuvant therapy for colorectal cancer failed to significantly ...

The ARIES-HM3 substudy may help persuade implanters who are less well-versed in the circulatory changes an LVAD affords.

In PACIFIC-STROKE, Bayer's drug ... aspirin plus a P2Y12 inhibitor – at one year. Once again, there was no significant observed increase in bleeding with asundexian at any dose or compared ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals ...

People without the risk of heart problems who consumed daily low-dose aspirin, it increased the chance of bleeding in the ...

A new international clinical trial led by the National Cancer Center Singapore is reporting that three years of aspirin ...

Gadoquatrane, a contrast agent Bayer is developing for use in MRI scans, like those done in MS, uses 60% less gadolinium and ...

Bayer meanwhile recently started a fourth phase 3 trial of elinzanetant that will test the drug's ability to treat VMS associated with endocrine therapy of breast cancer. GlobalData recently ...

aDivision of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Calgary, AB, Canada bDepartment of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine ...